Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
Company profile
Ticker
ZYME
Exchange
Website
CEO
Ali Tehrani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zymeworks Inc, Zymeworks Inc.
SEC CIK
Corporate docs
Subsidiaries
Zymeworks Biopharmaceuticals Inc. ...
ZYME stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
24 Oct 22
8-K
Entry into a Material Definitive Agreement
21 Oct 22
8-K
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
19 Oct 22
8-K
Amendments to Articles of Incorporation or Bylaws
18 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
POSASR
Automatic shelf registration (post-effective amendment)
13 Oct 22
25-NSE
Exchange delisting
13 Oct 22
Latest ownership filings
SC 13G/A
BANK OF AMERICA CORP /DE/
14 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
4
Neil Josephson
14 Nov 22
SC 13G
Redmile Group, LLC
8 Aug 22
4
Paul Andrew Moore
19 Jul 22
3
Paul Andrew Moore
19 Jul 22
4
Neil Josephson
5 Jul 22
4
Neil A Klompas
5 Jul 22
SC 13D/A
All Blue Falcons FZE
26 May 22
SC 13D/A
All Blue Falcons FZE
20 May 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 198.65 mm | 198.65 mm | 198.65 mm | 198.65 mm | 198.65 mm | 198.65 mm |
Cash burn (monthly) | 25.62 mm | 4.88 mm | 21.94 mm | 20.03 mm | 18.27 mm | 17.63 mm |
Cash used (since last report) | 558.40 mm | 106.26 mm | 478.17 mm | 436.48 mm | 398.27 mm | 384.17 mm |
Cash remaining | -359.75 mm | 92.39 mm | -279.52 mm | -237.83 mm | -199.62 mm | -185.52 mm |
Runway (months of cash) | -14.0 | 18.9 | -12.7 | -11.9 | -10.9 | -10.5 |
Institutional ownership, Q3 2023
16.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 74.38 mm |
Total shares | 11.41 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 5.87 mm | $51.60 mm |
All Blue Falcons FZE | 3.99 mm | $0.00 |
Fonds De Solidarite Des Travailleurs Du Quebec | 1.55 mm | $22.78 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Nov 22 | Neil Josephson | Common Stock | Sell | Dispose S | No | Yes | 8.099 | 2,475 | 20.05 k | 14,449 |
10 Nov 22 | Neil Josephson | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,885 | 0.00 | 16,924 |
10 Nov 22 | Neil Josephson | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 5,885 | 0.00 | 11,772 |